The Complainant is a global pharmaceuticals and healthcare company based in Switzerland and with a direct sales footprint in some 120 countries according to present data. The Complainant's history goes back some 250 years but the Novartis brand was adopted in 1996 with the establishment of the Novartis Group out of two earlier pharmaceutical firms, Ciba-Geigy and Sandoz. Novartis is one of the world's largest groups in its business sector and focuses on evolving needs of nearly 300 million patients worldwide by developing and delivering innovative medical treatments and drugs. In 2025, the Complainant achieved net sales of USD 54.5 billion and had over 75,000 employees. Its group has been present in Egypt for several decades and in 2024 opened new premises in the business district of New Cairo. Its offerings available there specifically include, as shown in screenshot evidence, the Novartis Patient Support service that extends to therapeutic guidance and advice on healthcare system reimbursements for medication up to financial assistance in some cases.<\/p>\n
The Complainant adduced evidence of a webpage to which the disputed domain name resolves that simply confirms registration of the domain name and website hosting is available. In addition, it submitted evidence showing that the Respondent has activated e-mail server addresses associated with the disputed domain name and that the Complainant had written a cease and desist letter to the Respondent. The Complainant avers that it received no response to its letter. Search results for online enquiries the Complainant made about the Respondent and the disputed domain name were also made. Finally, the Complainant adduced evidence as to its social media presence and as to this extending to Egypt.<\/p>\n
The Panel observes from the Registrar Verification that the Respondent, in the contact details given at registration, provides \"Novartesuport\" as the organization name, a postal address with the street name \"Road\" and a postcode in Cairo yet with New Cairo for \"state\" (i.e. region).<\/p>", "other_legal_proceedings": "
The Panel is not aware of any other legal proceedings which are pending or decided and relate to the disputed domain name.<\/p>", "no_response_filed": "
COMPLAINANT:<\/span><\/p>\n (1) The disputed domain name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights<\/span><\/p>\n The disputed domain name <novartisuport.com> incorporates in its stem the Complainant’s well-known trademark NOVARTIS in its entirety and the term “uport”. Addition of the term “uport” in the stem does not prevent a finding of confusing similarity to the Complainant's trademark while the presence of the generic gTLD extension <.com> is a standard registration requirement that may be disregarded when assessing whether the disputed domain name is confusingly similar. The disputed domain name is therefore confusingly similar to the Complainant’s trademark NOVARTIS. (2) The Respondent has no rights or legitimate interests in respect of the disputed domain name<\/span><\/p>\n The Complainant has never granted the Respondent any rights to use the NOVARTIS trademark in any way, including in the disputed domain name. There is no indication in this case that the Respondent is known by the disputed domain name or owns any corresponding registered trademarks; rather, online searches the Complainant made indicate the opposite. The Respondent has not been using, or preparing to use, the disputed domain name in connection with a bona fide offering of goods and services; nor is the Respondent making a legitimate non-commercial or fair use of the disputed domain name. The Respondent used a privacy shield service so as not to disclose the Respondent's contact details. Moreover, the structure of the disputed domain name, incorporating the Complainant’s trademark NOVARTIS in its entirety and the term “uport” – which read together may lead internet users to see “Novartis support” in the disputed domain name's stem – reveals the Respondent’s intention of registering the disputed domain name to refer to the Complainant, its trademark and business activity and to create an association, and a subsequent likelihood of confusion, with the Complainant and its NOVARTIS trademark in internet users’ minds. Indeed, as shown, the Novartis group offers Novartis Patient Support as a specific service. By reading the disputed domain name, internet users may indeed believe that it is directly connected or authorized by the Complainant, including in respect of its Novartis Patient Support service, and that the user's search will resolve to the Complainant’s official website, which is not the case. Instead, the disputed domain name resolves to a parking page. Accordingly, the disputed domain name is being passively held, and there is no evidence showing that the Respondent is using, or preparing to use, the disputed domain name legitimately.<\/span><\/p>\n (3) The disputed domain name was registered and is being used in bad faith<\/span><\/p>\n The Complainant’s trademark registrations significantly predate the registration of the disputed domain name. It is pertinent that the NOVARTIS trademark is a well-known trademark registered in many countries and having a strong presence online, including in Egypt. It is further relevant that the Respondent is based in New Cairo where Novartis Pharma S.A.E. has its premises. Simple online searches would have revealed information to the Respondent about the Complainant, its trademark and business. It is therefore implausible that the Respondent did not know about the Complainant, its products, and its NOVARTIS trademark when it registered the disputed domain name. Furthermore, the structure of the disputed domain name therefore reflects the Respondent’s clear intention to create an association, and a subsequent likelihood of confusion, with the Complainant’s trademark in internet users’ minds, while several factual considerations are clear indicators of bad faith use: the trademark's notoriety and distinctiveness; the disputed domain name resolving to a parking page (passive use); non-disclosure of identifying details; and the presence of active MX records with the corresponding risk that email addresses are being used. Internet users receiving emails from email addresses associated with the disputed domain name in the format<@novartisuport.com> may be led to believe that they are being personally contacted by the Complainant. Being so deceived, internet users might start to interact with the sender and possibly become victims of fraud attempts thanks to such impersonation of the Complainant.<\/span><\/p>\n RESPONDENT:<\/p>\n No administratively compliant Response has been filed.<\/p>",
"rights": " The Complainant has, to the satisfaction of the Panel, shown the disputed domain name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights (within the meaning of paragraph 4(a)(i) of the Policy).<\/p>",
"no_rights_or_legitimate_interests": " The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the disputed domain name (within the meaning of paragraph 4(a)(ii) of the Policy).<\/p>",
"bad_faith": " The Complainant has, to the satisfaction of the Panel, shown that the disputed domain name has been registered and is being used in bad faith (within the meaning of paragraph 4(a)(iii) of the Policy).<\/p>",
"procedural_factors": " The Panel is satisfied that all procedural requirements under the UDRP were met and that there is no other reason why it would be inappropriate to provide a decision.<\/p>\n The Panel notes that in its résumé of the Parties' contentions, citation of several decisions of past ADR panels contained in the Amended Complaint has not been repeated in the present decision since these are in view of this proceeding's factual circumstances not pertinent for arriving at determinations with reference to the UDRP.<\/p>",
"decision": "Accepted",
"panelists": [
"Kevin Madders"
],
"date_of_panel_decision": "2026-09-14 00:00:00",
"informal_english_translation": " The Complainant has adduced evidence that it owns the following trademarks for the NOVARTIS brand:<\/p>\n - International trademark No. 663765 registered on 1 July 1996 in Nice Classification List classes 1, 2, 3, 4, 5, 7, 8, 9, 10, 14, 16, 17, 20, 22, 28, 29, 30, 31, 32, 40, 42 (with Egypt designated); <\/p>\n - International trademark No. 666218 registered on 31 October 31 1996 in classes 41 and 42 (with Egypt designated); <\/p>\n - US trademark No. 2336960 registered on 4 April 2000 in classes 1, 5, 9, 10, 29, 30, 31, 32 and 42;<\/p>\n - EU trademark No. 13393641 registered on 17 March 2015 in classes 9 and 10;<\/p>\n - International trademark No. 1349878 registered on 29 November 2016 in classes 9, 10, 41, 42, 44 and 45 (with Egypt designated); <\/p>\n - International trademark No. 1544148 registered on 29 June 2020 in classes 9, 35, 38 and 42.<\/p>\n It also adduced evidence that the Complainant is the registrant of the domain name <novartis.com>, registered on 2 April 1996, as well as of its registration of the domain names <novatispharma.com> and <novatis.net>.<\/p>\n The Respondent registered the disputed domain name <novartisuport.com> on 1 April 2026 according to the Registrar Verification obtained by the CAC Case Administrator.<\/p>",
"decision_domains": {
"novartisuport.com": "TRANSFERRED"
},
"panelist": null,
"panellists_text": null
}
<\/span><\/p>\n